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Background: 17b-Oestradiol (E2)-induced reactive oxygen species (ROS) have been implicated in regulating the growth of breast
cancer cells. However, the underlying mechanism of this is not clear. Here we show how ROS through a novel redox signalling
pathway involving nuclear respiratory factor-1 (NRF-1) and p27 contribute to E2-induced growth of MCF-7 breast cancer cells.
Methods: Chromatin immunoprecipitation, qPCR, mass spectrometry, redox western blot, colony formation, cell proliferation,
ROS assay, and immunofluorescence microscopy were used to study the role of NRF-1.
Results: The major novel finding of this study is the demonstration of oxidative modification of phosphatases PTEN and CDC25A
by E2-generated ROS along with the subsequent activation of AKT and ERK pathways that culminated in the activation of NRF-1
leading to the upregulation of cell cycle genes. 17b-Oestradiol-induced ROS by influencing nuclear proteins p27 and Jab1 also
contributed to the growth of MCF-7 cells.
Conclusions: Taken together, our results present evidence in the support of E2-induced ROS-mediated AKT signalling leading to
the activation of NRF-1-regulated cell cycle genes as well as the impairment of p27 activity, which is presumably necessary for the
growth of MCF-7 cells. These observations are important because they provide a new paradigm by which oestrogen may
contribute to the growth of breast cancer.
Historically, a majority of breast cancer research has focused on
exploring conventional oestrogen receptor (ER) and growth factor
pathways with limited investigations on alternative mechanisms of
oestrogen action. Redox signalling as an alternative mechanism of
oestrogen-dependent breast tumor growth is rapidly emerging with
the promise of therapeutic potential. Physiologically achievable
concentrations of oestrogen increase reactive oxygen species (ROS)
formation in breast cancer cells (Felty et al, 2005a; Parkash et al,
2006). An increasing body of evidence supports the postulate that
oxidative stress generated from exposure to oestrogen, either
directly or by influencing the ER, may be an important driver in
the development and evolution of human breast cancer (Okoh
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et al, 2011; Penny and Roy, 2013). The role of ROS in breast cancer
is not new; however, a gap in knowledge currently exists with
regard to how oestrogen-induced ROS signals nuclear regulatory
proteins by way of redox-sensitive proteins. It is widely believed
that an impaired redox signalling pathway leads to the dysregu-
lated phosphorylation and/or dephosphorylation of proteins
involved in the activation or deactivation of nuclear regulatory
proteins (Okoh et al, 2011; Penny and Roy, 2013). We have
previously shown that 17b-estradiol (E2)-induced DNA synthesis
in MCF-7 breast cancer cells depends on mitochondrial oxidant
signalling to AP-1, CREB, and NRF-1 (Felty et al, 2005a; Parkash
et al, 2006). This study aims to extend our previous efforts in
understanding how an increase in ROS from E2 exposure
transduces a signal to nuclear regulatory proteins as well as to
identify the key downstream nuclear proteins responsible for the
growth of breast cancer cells. We demonstrate for the first time a
molecular mechanism of E2-induced activation of NRF-1 leading
to the upregulation of cell cycle genes; in addition, the impairment
of p27 activity through the ROS-inducible PI3K-PDK1/2-AKT
signal-transduction pathway may be necessary for E2-mediated
growth of MCF-7 breast cancer cells.
MATERIALS AND METHODS
Treatment of MCF-7 cells with ROS-scavenging enzymes. The
replication-defective, E1- and E3-deleted recombinant (Lam et al,
1997) adenovirus-CMV, adenovirus-MnSOD (MnSOD), and
adenovirus-catalase (CAT) constructs were purchased from
ViraQuest Inc. (North Liberty, IA, USA). MCF-7 cells were seeded
in plates at 15–70% confluence. On the following day, cells were
infected with different multiplicity of infection (MOI) of MnSOD,
CAT, or CMV virus particles in serum-free media (Okoh et al,
2013). Infected cells were cultured for 48 h, after which cells were
used for experiments. When noted in figure legends, cells were
treated by 500 mgml 1 of PEG-CAT.
RNA interference. Predesigned and tetracycline-inducible (Tet-
on/off) human shRNA TFAM (mitochondrial transcription factor
A) and AKT1 shRNA, pRS shRNA vector, shRNA COPS5 (Jab1),
and TrxR2 cDNA were purchased from OriGene Technologies Inc.
(Rockville, MD, USA). Predesigned NRF-1 shRNA and corre-
sponding scrambled constructs were purchased from Ambion
(Morrisville, NC, USA). Transfections of cells were carried out in a
subconfluent MCF-7 cell population using FuGENE 6 (Promega,
Madison, WI, USA). Transfection efficiencies ranged between 60
and 80% as quantified by decreased protein expression levels.
MCF-7 cells were transfected with Tet-on/off TFAM shRNA in
serum-free media for 48 h, after which cells were treated with
vehicle (dimethyl sulfoxide (DMSO)) or E2 (367.1 pM) for 24 h.
Mitochondrial transcription factor A expression was turned on by
the addition of 0.5mgml 1 doxycycline. Western blots were
probed with antibodies against TFAM and b-actin as a loading
control to verify the knockdown of TFAM protein level. For
shRNA knockdown of AKT expression, cells were transfected with
predesigned and verified human shRNA for AKT1 and control
shRNA plasmid consisting of scrambled shRNA sequence that
does not lead to the specific degradation of AKT1 (OriGene
Technologies Inc.). NRF-1 silencing cells were transfected with
predesigned and verified human shRNA for NRF-1 and control
shRNA plasmid consisting of scrambled shRNA sequence that
does not lead to the specific degradation of NRF-1. Cells were also
treated with Jab1 shRNA and control shRNA plasmid consisting of
scrambled shRNA sequence that does not lead to the specific
degradation of Jab1 (OriGene Technologies Inc.).
Colony formation assay. MCF-7 cells were seeded in six-well
plates with a bottom layer of 0.7% agar in DMEM/F12 and cells
were seeded on top in soft agar (0.3%) made in steroid-free
medium containing DMSO as a vehicle or E2 (367.1 pM), or
hydrogen peroxide (H2O2) (5, 25, or 600 mM) with and without
ROS or other modifiers (Okoh et al, 2013). Cells were fed weekly
with soft agar (0.3%) layer. Colony formation was recorded at
different time intervals after treatment, when cell masses grew to
100 mm or greater as measured by a Nikon TE2000U inverted
microscope (Melville, NY, USA).
Determination of ROS. MCF-7 cells were seeded at a concentra-
tion of 1.0 104 cells per well in 96-well plates and pretreated for
4 h with chemical antioxidants such as 20 mM ebselen (a glutathione
peroxidase mimic) or 1mM N-acetylcysteine (NAC) followed by
treatment with E2 (367.1 pM), 1 mM tamoxifen (TAM) citrate
(Sigma, St Louis, MO, USA), or vehicle (DMSO) for 30min.
Production of ROS was determined in MCF-7 cells treated with E2
(367.1 pM) in the presence or absence of ROS modifiers. MCF-7
cells overexpressing MnSOD and CAT or pretreated with ROS
scavengers ebselen or NAC for 4 h. MCF-7 cells were serum
starved for 48 h and pretreated with 10 mM of 20, 70-dichlorofluor-
escein-diacetate (DCFH-DA) (Molecular Probes, Eugene, OR,
USA) for 20min followed by treatment with E2. 20, 70-Dichloro-
fluorescein-diacetate is a non-fluorescent cell-permeable com-
pound, which is acted upon by endogenous esterase that remove
the acetate groups generating DCFH. In the presence of
intracellular ROS, DCFH is rapidly oxidised to the highly
fluorescent 20, 70-dichlorofluorescein (DCF). The oxidative pro-
ducts were measured with a Tecan Genios microplate reader
(Morrisville, NC, USA) using 485 and 535 nm excitation and
emission filters, respectively, as previously described by Felty et al
(2005a). Reactive oxygen species was also determined by a confocal
microscopy. The oxidation of ROS-sensitive dye DCFH-DA and
labelling mitochondria with MitoTracker Red were used to show
ROS formation in mitochondria of MCF-7 cells treated with TAM.
BrdU cell proliferation assay. Bromodeoxyuridine (BrdU) incor-
poration was determined as a biological indicator of DNA
synthesis in MCF-7 cells treated with E2 (367.1 pM) in the presence
or absence of ROS modifiers. MCF-7 cells overexpressing MnSOD
and CAT or pretreated with ROS scavengers ebselen (20 mM) or
NAC (1mM) for 4 h were exposed to E2 for 48 h before BrdU
incorporation. MCF-7 cells were grown (2500 cells per well) in 96-
well plates until 50% confluent in 10% FBS DMEM/F12, and then
serum starved for 48 h followed by the treatment. Cells were
pretreated for 4 h with ROS scavengers 20 mM ebselen or 1mM
NAC followed by treatment with E2 (367.1 pM). Next, cells were
labelled with BrdU for 24 h. Afterwards, a colorimetric BrdU cell
proliferation assay was performed according to the manufacturer’s
instructions (Roche, Branford, CT, USA) as described previously
(Felty et al, 2005b). Absorbance of the samples was measured in a
Tecan Genios microplate reader at 450 nm (reference l at 700 nm).
Cell viability and ATP assays. Cell viability was measured using
the CellTiter-Fluor Cell Viability Assay Kit (Promega), which
measures conserved constitutive protease activity in live cells.
Quantitation of the ATP present in the MCF-7 cells exposed to
vehicle (DMSO) or E2 (367.1 pM) for 0.5 and 16 h was carried out
by recording the luminescence of CellTiter-Glo Reagent
(Promega).
Electrophoretic mobility shift assay. Electrophoretic mobility
shift assay (EMSA) was performed with DIG-11-ddUTP 30-end
labelled probes. The oligonucleotide sequences used for EMSA
were as follows: the NRF-1 consensus sequence from human
TFA promoter region (NRF-1 forward primer, 50-CGCTCTCC
CGCGCCTGCGCCAATT-30; NRF-1 reverse primer, 5’-GGGCGG
AATTGGCGCAGGCGCGGG-30). Probe labelling and binding
reactions were performed using the DIG Gel Shift Kit (Roche)
following the protocols provided by the manufacturer as described
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previously (Felty et al, 2005a). Nuclear extracts were collected and
5mg of extract was loaded for all samples. Samples were
electrophoresed on a 6% native polyacrylamide gel and transferred
to a nylon membrane by electroblotting. Binding was detected by
chemiluminescent detection as described in the DIG Gel Shift Kit
protocol (Roche). A competitive binding reaction with 100-fold
higher concentration of unlabelled oligos as compared with
labelled oligos in both vehicle (DMSO) and E2 treatments served
as the negative control.
Antibodies and immunoblotting analysis. Lysates from MCF-7
cells overexpressing MnSOD and CAT or pretreated with ROS
scavengers ebselen (20 mM) or NAC (1mM) for 4 h were exposed to
E2 (367.1 pM) for 30min before being processed for western
blotting and were probed with the following antibodies ERK1/2,
p-ERK1/2, p27, p27(T157)-P, ERa, p-ERa, Jab1, TFAM, PTEN, or
CDC25A (Santa Cruz, Dallas, TX, USA), anti-NRF-1 (Rockland,
Limerick, PA, USA), phosphorylated AKT (p-AKT) (Ser 473) and
total AKT antibodies (Cell Signaling), GAPDH, or b-actin (Sigma).
For immunoprecipation experiments, total cell lysates of DMSO-
or E2-treated (367.1 pM for 30min) MCF-7 cells were immuno-
precipitated (IP) with anti-NRF-1 or anti-CDC25A antibodies, and
immunoblots were probed with anti-NRF-1, anti-AKT, antipho-
sphoserine, or antityrosine antibodies.
Redox western blot analysis. MCF-7 cells (1 106) seeded into
100mm plates were pretreated with 10mM erucin for 48 h followed
by DMSO or E2 (367 nM) treatment for 30min. A total of 50 mg
protein was resolved by 15% SDS–PAGE under non-reducing
conditions subjected to immunoblot analysis using anti-Trx and
b-actin antibodies as previously described by Watson et al
(2003).Total proteins were resolved by 15% SDS–PAGE under
non-reducing conditions and were detected using an anti-Trx
antibody. Steady-state redox potential (Eh, redox state) was
calculated using the Nernst equation (EoTrx1¼  240mV, pH
7.4), as described by Watson et al (2003). Protein bands
corresponding to reduced and oxidised forms of Trx were recorded
on X-ray films or as Versadoc images and then subjected to
densitometry analysis using the ImageJ software. Quantified
protein band intensities of oxidised and reduced Trx bands were
used for the calculation of EhTrx and the steady-state redox
potential. The oxidised state of PTEN was detected by EMSA using
the alkylating agent N-ethylmaleimide, by in MCF-7 cells. In brief,
the oxidation state of PTEN was investigated using alkylating
agents, in cell lysates from E2 (367 nM) or TAM (1mM) for 30min
and untreated cells grown in the absence and presence of 10mM
ebselen. Total protein lysates were resolved by 10% SDS–PAGE
under non-reducing conditions. Reduced and oxidised forms of
PTEN were detected by immunoblot analysis with rabbit anti-
PTEN. To assess the cysteine oxidation in CDC25A by E2-induced
ROS, lysates from E2-treated cells (367 nM) for 30min and
untreated cells grown in the absence and presence of 10mM
NAC were labelled with a sulphydryl-specific reagent 5-iodoace-
tamidofluorescein (5-IAF), obtained from Pierce (Rockford, IL,
USA) using the protocol of Wu et al (1998), IP with anti-CDC25A,
and detected using rabbit antifluorescein. Immunoglobulin G level
was used as a loading control of each IP sample.
Assay of CDC25A phosphatase activity. CDC25A phosphatase
activity was measured at pH 7.4 and at ambient temperature with
the artificial substrate O-methylfluorescein phosphate (OMFP) in a
96-well microtiter plate assay based on the method described by
Lazo et al (2001). MCF-7 cells were lysed and IP with
phosphoserine agarose-coupled antibodies followed by western
blotting with anti-CDC25A antibodies. The total cell lysate was
analysed for CDC25A phosphatase activity using OMFP as the
substrate.
In vitro kinase assays. Recombinant human NRF-1 (50 ng) alone
or in combination with 1mg recombinant human AKT was
incubated in 30 ml kinase buffer with or without 200 mM ATP for
10min at 30 1C. Cell lysates were subjected to 8% SDS–PAGE and
probed with anti-phosphoserine and anti-NRF-1 antibodies.
Identification of NRF-1 phosphorylation sites by mass spectro-
metry. Several AKT phosphotyrosine sites were detected by
tandem mass spectrometry (MS/MS) methods. Tandem mass
spectra were searched against the reversed and concatenated Swiss-
Prot protein database using the Sequest algorithm (Proteomics
browser; Thermo Scientific, Rockford, IL, USA) with differential
modifications for STY phosphorylation (þ 79.97) and methionine
oxidation (þ 15.99). Phosphorylation sites were identified if they
initially passed the following Sequest scoring thresholds. Determi-
nation of the exact sites of phosphorylation was aided using the
GraphMod software (Proteomics browser; Thermo Scientific).
Immunofluorescence staining. The fluorescent probe Mito-
Tracker Red was used for labelling of mitochondria (fluorescence
intensity as a surrogate for mitochondrial mass). Images of
MitoTracker Red 580 incorporation in mitochondria ( 40) were
acquired by fluorescence confocal microscopy after 15min of
adding E2 or DMSO, as described by Parkash et al (2006). MCF-7
cells were seeded and treated in chamber slides. After E2 treatment,
cells were fixed with ice-cold methanol for 15min, and
permeabilised with 0.5% Triton X-100 for 30min. Cells were then
incubated with primary antibodies and Alexa Fluor-conjugated
secondary antibodies. The confocal fluorescence images were
scanned on a Nikon TE2000U inverted microscope. The
fluorescent probe MitoTracker Red was used to label mitochondria
and its fluorescence intensity was monitored as an indirect
measure of mitochondrial mass. Images of MitoTracker Red 580
incorporation in mitochondria were acquired by fluorescence
confocal microscopy after 15min of adding E2 or DMSO, as
described previously (Parkash et al, 2006). The confocal images
were acquired on a Nikon C1 laser scanning confocal microscope
(Melville, NY, USA). In vivo phosphorylation of endogenous NRF-
1 by E2 treatment was determined by immunofluorescent labelling
with Alexa Fluor 488-mouse anti-phosphoserine and NRF-1-anti-
rabbit antibodies (Alexa Fluor 633-conjugated secondary anti-
body). In vivo phosphorylation of ER by E2 treatment was
determined by immunofluorescent labelling. In vivo phosphoryla-
tion of p27 by E2 treatment was determined by immunofluorescent
labelling. MCF-7 cells were stained with immunofluorescent p27
and p27(T157)-P antibodies and conjugated with Alexa Fluor 488
and 635-labelled secondary antibody conjugates, respectively, and
analysed by confocal microscopy for localisation of p27Kip1 and
p27(T157)-P. For semiquantitation, p27-, p27(T157)-P-, ERa-, and
p-ERa-immunopositive cells, in which4300 cells were counted in
three independent experiments.
ChIP qPCR to analyse NRF-1 binding to the promoters of cell
cycle genes. Chromatin immunoprecipitation assays (ChIP) were
carried out with the ChIP Assay Kit (Upstate Biotechnology, New
York, NY, USA). MCF-7 cells (3 106) overexpressing MnSOD or
CAT were treated with either E2 (367.1 nM) for 16 h or analysed by
ChIP assay using the anti-NRF-1 antibody. DNA from chromatin
IP with anti-NRF-1 antibodies was amplified with primers specific
for the PRC1, CDC2, PCNA, cyclin B1, and CDC25C promoter
region containing NRF-1 sites using an ABI Biosystem 7300
thermocycler (Grand Island, NY, USA) with the following cycle
conditions: initial 10min at 95 1C followed by 40 cycles of 95 1C,
15 s and 60 1C, 60 s. Chromatin immunoprecipitation qPCR results
were calculated using the DDCt method.
Oestrogen-induced redox signalling and breast cancer BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.586 1689
Real-time qRT–PCR analysis. Total RNAs were isolated with
TRIzol reagent (Life Technologies, Grand Island, NY, USA) from
MCF-7 cells exposed to E2 for 16 h in the presence and absence of
ROS modifiers using the ChIP assay condition. The RNA templates
were reverse transcribed into cDNA using reverse transcription
reagents with random hexamer primers (Applied Biosystems,
Grand Island, NY, USA). The cDNA was then used as the
template for real-time PCR with gene-specific primers. The
TaqMan primers of PRC1, CDC2, PCNA, cyclin B1, CDC25C,
and 18S were used. Quantitative gene expression analysis
was performed by TaqMan-based qRT PCR on ABI 7700 (PE
Applied Biosystems, Foster City, CA, USA).
RESULTS
ROS-scavenging enzymes suppress E2-induced DNA synthesis
of MCF-7 cells. Our previous studies have shown that mitochon-
dria are a major site of E2-induced ROS in breast cancer cells (Felty
et al, 2005a; Parkash et al, 2006). The specific individual ROS that
is most relevant to E2 signalling pathophysiology has yet to be
identified. As the antioxidants ebselen and NAC are nonspecific in
the type of ROS scavenged, we chose to overexpress antioxidant
enzymes. The mitochondrial antioxidant enzyme MnSOD dis-
mutates O2
 . Therefore, we determined whether increased
formation of O2
 signalled E2-induced DNA synthesis by
overexpressing MnSOD. Within the mitochondria, MnSOD can
dismutate O2
 to H2O2, which is a highly diffusible signalling
molecule that can exit the mitochondria. Thus, we also determined
whether increased H2O2 formation signalled E2-induced DNA
synthesis by overexpressing CAT. We used intracellular DCFH-DA
oxidation method to measure the endogenous ROS levels in the
MCF-7 cells exposed to an E2 concentration equivalent to the
physiological and pharmacological levels in the target tissue
(367.1 pM) for 30min in the presence or absence of ROS
scavengers. As expected, E2 treatment induced significantly more
ROS in MCF-7 cells compared with vehicle control. The ability of
E2 to produce ROS was prevented by treatment with chemical ROS
scavengers ebselen or NAC (Figure 1A). Both ebselen and NAC
inhibited E2-induced BrdU incorporation in the MCF-7 cells.
These findings are in agreement with our previous studies (Felty
et al, 2005a, b). When MnSOD was overexpressed in MCF-7 cells,
ROS levels increased significantly compared with cells with empty
vector (CMV). 17b-Oestradiol-exposed MCF-7 cells transduced
with MnSOD at an MOI of 200 or 200 virus particles showed a
400% increase in ROS production and less BrdU incorporation
compared with control cells (Figure 1B). 17b-Oestradiol-exposed
MCF-7 cells transduced with CAT at an MOI of 200 produced
130% less ROS and incorporated less BrdU compared with E2-
treated MCF-7 cells with the vector alone (Figure 1B). We also
measured cellular protease activity to rule out the possibility that
the changes in ROS levels were not as a result of different cell
densities or viability. There was no change in protease activity
between MCF-7 cells transduced with MnSOD and CAT or empty
CMV vector adenoviral constructs (data not shown). These
findings further support that H2O2 and O2
 have an important
role in E2-mediated growth of breast cancer cells.
ROS modifiers modulate E2-induced colony-forming activity of
MCF-7 breast cancer cells. As long-term (21 days or longer)
survival of colonies in semisolid media is considered an important
phenotypic property of most cancer cells (Aapro et al, 1987) and
strongly correlates with tumorigenicity in experimental animals,
we reasoned that if E2 is responsible for the promotion and
progression of breast tumor, then ROS may also contribute to
colony-forming phenotypic ability of MCF-7 breast cancer cells.
Therefore, we used the clonogenic assay instead of monolayer
liquid cell culture to monitor whether E2-induced ROS promoted
the ability of MCF-7 cells to form colonies. As expected, the ability
of MCF-7 to form colonies on soft agar was significantly higher in
E2-treated cells (100 pgml 1 for 21 days) compared with control
cells. Treatment of cells with ROS scavengers (20 mM ebselen or
1mM NAC) significantly inhibited colony formation in E2-treated
MCF-7 cells (Figure 1C). MCF-7 cells overexpressing CAT (protein
levels confirmed by western blot) produced lower levels of ROS
and fewer colonies when compared with E2-treated cells with
vector alone (Figure 1D). This implies that when ROS levels were
diminished by biological or chemical modifiers, E2-induced colony
formation of MCF-7 cells was inhibited. However, this phenom-
enon was not observed in MnSOD-overexpressing cells. As shown
in Figure 1B, MCF-7 cells transduced with MnSOD at an MOI of
200 showed a significant increase of ROS production and reduced
MCF-7 colony formation in E2 treatment (Figure 1D). We
observed that MCF-7 cells treated with MnSOD at an MOI of
5–50 showed an increased number and size of colonies, whereas an
MnSOD dose 450MOI diminished MCF-7 colony formation
(Figure 1E and F). The adenovirus-containing control vectors
(50MOI) did not produce any growth advantage compared with
wild-type MCF-7 cells. The observed reduction of MCF-7 cell
growth by treatment with MnSOD 450MOI was not because of
cell death, as we found that over 70% of adenoviral-infected cells
were viable up to a dose of 200MOI based on the Trypan blue
assay, whereas 90% of the cells treated with MnSOD at 400MOI
were not viable at 21 days of culture in soft agar assay (data not
shown). The suppression of the number and size of MCF-7
colonies were dependent on the MOI of the adenoviral constructs
containing MnSOD, CAT or CMV. Our data showed that when
cells were treated at lower MOI of MnSOD, the number and size of
colonies increased, while at higher MOI both parameters in cell
colonies decreased. High levels of H2O2 produced by treatment
with MnSOD at an MOI of 200 (4400% ROS compared with
control; Figure 1E and F) presumably inhibited E2-induced growth
of MCF-7 colonies. To test this postulate, we examined the effect of
various concentrations of H2O2 on MCF-7 colony formation after
7 days of treatment in the presence or absence of H2O2 scavenger
(PEG-CAT). Consistent with our postulate, we found that when
cells were treated at a low concentration of H2O2 (25 mM), the
number and size of colonies were increased by more than two-fold
compared with controls and these effects of H2O2 on MCF-7
colony were prevented by cotreatment with 500 mgml 1 PEG-
CAT. Whereas at a high concentration of H2O2 (600 mM), both
parameters in cell colonies were lower than controls (Figure 1G).
This is consistent with reports that lower levels of H2O2 support
the growth of cells, while higher levels of H2O2 are toxic to cells,
perhaps by inducing autophagic programmed cell death (Deruy
et al, 2010). These observations suggest that ROS, particularly
H2O2 and O2
 , produced by E2 treatment may have an important
role in the colony-forming ability of MCF-7 cells.
Cell proliferation and colony formation of E2-treated MCF-7
cells depend on the oxidative state of Trx. The thioredoxin (Trx)
system consisting of Trx, NADPH, and Trx reductase (TrxR)
functions in thiol-dependent thiol-disulphide exchange reactions,
which are crucial in control of the reduced intracellular redox
environment. We postulate that these proteins (Trx/TrxR) are
responsive to E2-induced ROS in exposed cells and oxidation of
these proteins may modulate E2-induced growth of MCF-7 cells.
We first determined whether E2-exposed cells showed a change in
the redox status of Trx. As expected, we observed higher levels of
oxidised Trx after H2O2 treatment, while the DTT treatment
reduced Trx (Figure 2A). MCF-7 cells treated with E2 (367.1 pM)
showed significant oxidation of Trx at 30min as shown by redox
western blot (Figure 2A) and calculated redox potential (EhTrx1)
BRITISH JOURNAL OF CANCER Oestrogen-induced redox signalling and breast cancer
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measurements (Figure 2B). Erucin has been shown to be a potent
inducer of TrxR in MCF-7 cells (Wang et al, 2005a); therefore, we
examined the effects of erucin on E2-induced oxidation of Trx. As
shown in Figure 2A, pretreatment with erucin suppressed the level
of oxidised Trx, presumably through an increase in Trx reductase
levels that were able to handle the increased level of E2-induced
ROS. These experiments show that the oxidation of Trx occurs by
E2 treatment and redox potential of MCF-7 cells is shifted towards
a reduced environment. After confirming that E2 treatment
oxidised Trx in MCF-7 cells, we determined the effects of Trx
modifier erucin on E2-induced cell proliferation and colony
formation in MCF-7 cells. We observed that the dose of erucin
(10 mM) already reported induce the expression of TrxR (Wang
et al, 2005a) significantly decreased BrdU incorporation and
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Figure 1. Endogenous ROS regulated E2-induced growth of MCF-7 cells. Production of ROS and bromodeoxyuridine (BrdU) incorporation was
determined in MCF-7 cells treated with E2 (367.1pM) in the presence or absence of ROS modifiers. MCF-7 cells overexpressing manganese
superoxide dismutase (MnSOD), catalase (CAT), or pretreated with ROS scavengers ebselen (Eb) (20mM) or 1mM of NAC for 4 h were exposed to
vehicle (dimethyl sulphoxide (DMSO)) or E2 (367.1pM) for 30min before ROS measurements or for 48 h for BrdU incorporation. (A) Analysis of ROS
by DCF assay and BrdU incorporation assay in MCF-7 cells either transduced with 50MOI of MnSOD and CAT or pretreated with ROS scavengers.
(B) Analysis of ROS formation and BrdU incorporation in MCF-7 cells transduced with 200MOI of MnSOD and CAT or pretreated with ROS
scavengers. Values are mean±s.d. of six independent experiments. (C) Effect of ROS scavengers on colony formation in soft agar of E2-treated
MCF-7 cells after 21 days. (I) Vehicle control (CTRL), (II) E2, (III) Eb, (IV) EbþE2, (V) NAC, and (VI) NACþE2. Bar graph indicates significant
inhibition of E2-induced colonies by ROS scavengers. Values for the number of colonies are shown as fold change compared with CTRL.
(D) Colony assay of E2-treated MCF-7 cells overexpressing MnSOD, CAT, and CTRL vector after 21 days. (I) CTRL vector, (II) vectorþE2, (III) CAT,
(IV) CATþE2, (V) MnSOD, and (VI) MnSODþE2. Bar graph indicates significant inhibition of E2-induced colonies by ROS scavengers. Western
blot confirmed overexpression of CAT and MnSOD (MOI¼200) in MCF-7 cells. (E) Effect of MnSOD overexpression on MCF-7 colony formation.
MCF-7 cells were transduced with various titers of MnSOD (5–400MOI). (F) Bar graph of the effect of MnSOD treatment on MCF-7 colony number
and size. Colony efficiency for (C, D, and F) were determined by counting the number of colonies465mm in diameter. Data were expressed as the
mean of five wells±s.d. (G) Effect of various concentration of H2O2 in the presence or absence of PEG-CAT on MCF-7 colony formation after
7 days of treatment. Bar graph of the effect of H2O2 treatment on MCF-7 colony number and size. Values are mean±s.d. of three independent
experiments. (H) ATP levels present in the MCF-7 cells exposed to vehicle (DMSO) or E2 (367.1pM) for 0.5 and 16h. ATP levels in the cells were
measured by recording the luminescence of CellTiter-Glo Reagent (Promega). *Po0.05, significant difference from that of CTRL. **Po0.05,
significant difference from E2 or H2O2 treatment.
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colony formation in both control- and E2-treated MCF-7 cells
(Figure 2C). Next, we confirmed these results by directly
overexpressing the enzyme TrxR2. As expected, we observed that
the overexpression of TrxR2 (confirmed by western blot) decreased
the proliferation and colony formation of E2-treated MCF-7 cells
when compared with vehicle control (Figure 2D). Taken together,
these findings support a role of the Trx system in controlling
E2-induced growth of MCF-7 cells.
Role of mitochondria in regulating ROS production and
prevention of E2-induced MCF-7 colony formation. Previously,
we have reported that E2-induced growth of MCF-7 cells depend in
part on ROS of mitochondrial origin (Felty et al, 2005a).
Mitochondria are highly dynamic organelles, frequently dividing
and fusing in response to physiological and environmental
conditions. To further establish that the growth of MCF-7 cancer
cells is mediated by ROS produced by mitochondria, we examined
the effect of inhibition of genes responsible for mitochondrial
biogenesis. The effect of E2 treatment on mitochondrial mass was
examined by confocal microscopy. The fluorescent probe Mito-
Tracker Red was used to label mitochondria and its fluorescent
intensity served as a surrogate for mitochondrial mass. As shown
in Figure 2E, E2 treatment (367.1 pM) increased MitoTracker
Red 580 labelling, indicating E2 treatment increased MCF-7
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effects on ROS formation, BrdU incorporation, and cell viability in E2-treated MCF-7 cells. Values are mean±s.d. Data shown in each panel are
representative of three independent experiments. *Po0.05, significantly different from CTRL. **Po0.05, significantly different from E2.
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cells mitochondrial mass (Figure 2E). Mitochondrial transcription
factor A controls mitochondrial biogenesis (Okoh et al, 2011).
Mitochondrial transcription factor A is known to regulate not only
mitochondrial biogenesis but also mtDNA stability and the
biosynthesis of the 13 mtDNA-encoded respiratory chain subunits.
As E2 treatment showed an increase in the mitochondrial mass, we
postulated that E2 increased the DNA-binding activity of NRF1, a
regulator of TFAM as well as the level of TFAM. Using EMSA, we
observed a several fold increase in NRF1 DNA-binding activity as
early as 3 h (Figure 2E) in treated MCF-7 cells. As shown in
Figure 2F, E2 treatment (367.1 pM for 24 h) resulted in a two-fold
increase in total TFAM protein that was inhibited by treatment with
inducible TFAM shRNA system. Western blot analysis confirmed
inhibition of the levels of TFAM protein by shRNA treatment.
Inducible TFAM shRNA inhibited MCF-7 colony formation in E2-
treated cells (Figure 2G). We also determined whether the observed
reduction in MCF-7 colonies was due to cell death from TFAM
knockdown. The percentage of viable cells in both treatment groups
for TFAM shRNA was very similar to control cells (Figure 2H).
Furthermore, knockdown of TFAM resulted in the inhibition of E2-
induced ROS that was to be expected because we have already
showed that mitochondria are a major source of ROS in E2-treated
MCF-7 cells. DNA synthesis was inhibited in E2-exposed MCF-7
cells by the silencing of TFAM (Figure 2H), which is corroborated
by our previous study that showed MCF-7 r0 cells had decreased
E2-induced DNA synthesis because of impaired mitochondrial
biogenesis (Felty et al, 2005b). To discern whether a decrease in ATP
production or ROS may be responsible for the E2-induced growth
signalling, we measured the ATP present in the MCF-7 cells exposed
to vehicle (DMSO) or E2 (367.1 pM) for 0.5 and 16h (Figure 1H).
Our data showed that the ATP levels in both treatment groups for
E2 were very similar to control cells. This is consistent with our
previous studies in MCF-7 cells, indicating that modulation of
mitochondrial function, mitochondrial protein synthesis, or mito-
chondrial transcription/replication block E2-induced cell cycle
progression from G1 to S phase without influencing the level of
ATP (Felty et al, 2005b). Taken together, these data suggest that
mitochondria are a source of E2-induced ROS, which in part
contribute to the growth of MCF-7 cells.
Oxidation of PTPs and ROS-induced phosphorylation of ERK
and AKT in E2-treated MCF-7 cells may be responsible for the
growth of breast cancer cells. Here the aim was to identify the cell
signalling mechanism contributing to the growth of malignant breast
cancer cells. We previously showed that E2-induced DNA synthesis
in MCF-7 breast cancer cells depends, in part, on ROS-mediated
signalling to nuclear transcription factors, including NRF-1 (Felty
et al, 2005a). The question that remains unanswered is how E2-
induced ROS transduce a signal to nuclear regulatory proteins that
participate in breast cancer cell growth. We postulated that the
transient inhibition of protein tyrosine phosphatases (PTPs) through
the reversible oxidisation of their catalytic cysteine ultimately
suppresses protein dephosphorylation of PTP-interacting proteins.
Furthermore, we postulated that this redox-sensitive pathway is
coupled to the activation of downstream nuclear regulatory proteins
in response to E2-induced ROS signalling. Therefore, we investigated
the effects of E2-mediated redox regulation of PTPs (PTEN and
CDC25A) and their downstream effects on PTP-regulated proteins
(ERK and AKT) that ultimately signal nuclear regulatory proteins
(NRF-1, ERa and p27) in MCF-7 cells.
Endogenous ROS regulated E2-induced oxidation of PTEN and
CDC25A. Signal transduction by ROS through reversible PTP
inhibition may be a major mechanism used by E2-dependent
breast cancer cells. 17b-Oestradiol treatment has been shown to
cause a significant decrease of PTEN activity (Marino et al, 2003).
Reactive oxygen species such as H2O2 and superoxide also decrease
PTEN activity through the oxidation of PTEN’s cysteine residues
(Lee et al, 2002). Therefore, we measured whether the inhibition of
PTEN by E2 is mediated by ROS. First, we confirmed whether
H2O2, known to oxidise PTPs, could oxidise PTEN in MCF-7 cells
(Lee et al, 2002). As shown in Figure 3A, 0.2mM H2O2 did not
induce PTEN oxidation and treatment with reductant DTT
showed only reduced form of PTEN. There was no difference in
PTEN oxidation in untreated MCF-7 cells and 0.2mM H2O2-
treated MCF-7 cells (data not shown). Treatment of MCF-7 cells
with higher doses of H2O2 (0.5–1.0mM) produced very pro-
nounced oxidised form of PTEN compared with that of 0.2mM
H2O2-treated MCF-7 cells. As we showed previously, treatment
with TAM and E2 increased the level of ROS in MCF-7 cells.
Therefore, we first determined the oxidation of PTEN in E2-treated
MCF-7 cells. Our results showed that E2 treatment increased
PTEN oxidation (Figure 3B), which was inhibited by cotreatment
with the ROS scavenger ebselen.
We also tested the effects of E2-induced ROS on CDC25A
because it contains a highly reactive cysteine at the active site that
can react directly with ROS, leading to enzyme inactivation and
thus may be another potential redox-sensitive PTP. The oxidation
of CDC25A was determined in MCF-7 cells treated with E2 or
H2O2. MCF-7 cells showed increased oxidative modification
(decreased 5-IAF labelling) of CDC25A to E2 (Figure 3C) as well
as a parallel decrease in phosphatase activity in response to E2 and
H2O2 (Figure 3D). Furthermore, we determined the effects of E2
and H2O2 on serine phosphorylation of CDC25A (Figure 3E).
Cotreatment with ROS scavenger NAC not only counteracted E2-
induced oxidative modification of CDC25A, which was shown by
increased 5-IAF labelling in NACþ E2 group compared with E2
alone (Figure 3C), but also prevented the decrease in CDC25A
phosphatase activity from E2 treatment (Figure 3D) that was
supported by an associated decrease in phosphorylation
(Figure 3E). In contrast to serine phosphorylation of CDC25A,
we observed an increase in tyrosine phosphorylation in cells
treated with E2 or H2O2 (Figure 3F) and this was inhibited by
cotreatment with NAC. To rule out whether a decrease in CDC25A
activity under conditions of E2-induced ROS was not because of
the degradation of CDC25A protein, we analysed CDC25A levels
in the presence and absence of the ROS scavenger NAC. As shown
in Figure 3G, we observed an increase in the level of CDC25A
protein as early as 3 h after E2 exposure. Cotreatment with ROS
scavenger NAC or mitochondrial complex I inhibitor rotenone,
which was known to block mitochondrial oxidant generation,
showed a decrease in E2-induced CDC25A protein compared with
control. These findings suggest that the decrease in CDC25A
phosphatase activity by E2 treatment was not because of the
degradation of CDC25A, but rather these data support the idea
that E2-induced ROS may inhibit phosphatase activity, presumably
by oxidation of the Cys-SH residue perhaps by modulating serine
phosphorylation of CDC25A.
Endogenous ROS regulated E2-induced ERK and AKT phosphor-
ylation. Both ERK and AKT are important kinases regulated by E2
and are downstream components of a signalling pathway involving
PTPs CDC25A and PTEN. Phospho-ERK has been shown to be a
substrate of CDC25A (Wang et al, 2005). Therefore, we determined
whether treatment with ROS scavengers decreased E2-induced
phosphorylation of ERK. As shown in Figure 3H, a 30min treatment
of MCF-7 cells with E2 (367.1 pM) increased the levels of
phosphorylated ERK. This is in agreement with previous studies
(Migliaccio et al, 1996; Marino et al, 2003). Next, we determined
whether E2-induced increase in p-ERK depended on ROS. As shown
in Figure 3H, overexpression of CAT and MnSOD inhibited the
phosphorylation of ERK in E2-treated MCF-7 cells, but did not affect
Oestrogen-induced redox signalling and breast cancer BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.586 1693
ERK protein expression (Figure 3H). The data suggest that ERK1/2
activation is a downstream effector of E2-induced ROS. Given the
previous observations that CDC25A interacted with ERK and
CDC25A was oxidised in E2-treated MCF-7 cells, the subsequent
inhibition of CDC25A phosphatase activity may allow for the
continued phosphorylation of ERK (Wang et al, 2005).
As PTEN through the phosphoinositol 30 kinase (PI3K) pathway
is known to regulate AKT, we also determined the effect of ROS
modifiers on phosphorylation of AKT in E2-treated MCF-7 cells.
As expected, treatment of MCF-7 cells increased phosphorylation
of AKT (Figure 3I). 17b-Oestradiol -induced phosphorylation of
AKT was reduced by either overexpression of antioxidant enzymes
CAT or MnSOD and ROS scavengers ebselen or NAC. There was
no difference in the phosphorylation of AKT in vehicle- and
NAC-, rotenone-, or ebselen-treated cells (background levels, data
not shown). Therefore, we have used the same controls as a
representation for both vehicle- and NAC-, rotenone-, or ebselen-
treated control experiments. Studies of the mitochondrial electron
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Figure 3. Oxidation of PTPs and ROS-induced phosphorylation of ERK and AKT in E2-treated MCF-7 cells. Changes in the oxidation state of
PTPs, PTEN, and CDC25A were determined by western blot analysis. (A) Comparison of PTEN oxidation in MCF-7 cells treated with oxidant H2O2
and reductant dithiothreitol (DTT) (5mM) for 30min. Higher doses of H2O2 (0.5 and 1.0mM) showed higher levels of oxidised PTEN (bottom band)
compared with 0.2mM dose of H2O2 and DTT. (B) Comparison of PTEN oxidation in E2-treated MCF-7 cells when pretreated with 20mM of ROS
scavenger ebselen (Eb) for 4 h. Western blot showed increased PTEN oxidation by both E2 (367 nM) and 1 mM tamoxifen (TAM) treatment in MCF-7
cells compared with control (CTRL) (dimethyl sulfoxide (DMSO)) and this was suppressed by Eb. Values in graph represent % oxidised/reduced
PTEN from three independent experiments±s.d. (C) Comparison of CDC25A sulphydryl labelling by 5-iodoacetamidofluorescein (5-IAF) reagent
in MCF-7 cells treated with E2 (10 ngml 1) for 30min in the presence or absence of 10mM of ROS scavenger NAC. Decreased 5-IAF labelling
indicated a decrease in free sulphydryl (SH) groups present in CDC25A. (D) Analysis of CDC25A phosphatase activity in MCF-7 cells treated with
E2 and H2O2 as described previously. Values in the graph represent CDC25A phosphatase activity from IP lysate of MCF-7 cells treated with NAC.
Enzyme activity was tested in vitro using OMFP as a substrate. (E) Comparison of CDC25A serine phosphorylation in E2- and H2O2-treated MCF-7
cells when pretreated with NAC as described previously. (F) Comparison of CDC25A tyrosine phosphorylation in E2- and H2O2-treated MCF-7
cells when pretreated with NAC as described previously. Cell lysates were IP with CDC25A antibody and immunoblots were detected for anti-
phosphotyrosine (p-Tyr) or -serine (p-Ser). IgG bands served as a loading CTRL (n¼2). (G) Western blot analysis of the effects of NAC (10mM) and
mitochondrial ROS blocker rotenone (Rot) (5 mM) on CDC25A protein levels in E2-treated MCF-7 cells. (H) Western blot analysis of the effects of
MnSOD and CAT (MOI¼200) overexpression on E2 (367pM)-induced ERK phosphorylation in MCF-7 cells. Values in the graph represent a ratio of
levels of phospho-ERK1/2 compared with total ERK1/2 or b-actin from three independent experiments. (I) Western blot analysis of the effect of
ROS modifiers on E2-induced AKT phosphorylation in MCF-7 cells. Experimental conditions are the same as described previously. Treatment with
10mM of PI3K/AKT pathway inhibitor LY294002 (Ly) served as a positive CTRL of p-AKT inhibition. Values in the graph are the densitometry data of
p-AKT normalised to total AKT expressed as fold change compared with CTRL. The quantitative values are mean±s.d. Data shown in this figure
are representative of three independent experiments. *Po0.05, significant difference from CTRL. **Po0.05, significant difference from E2. SOD,
superoxide dismutase.
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transport chain have reported ROS-forming sites at the FMN
group of complex I (Turrens et al 1985). Therefore, we used a
specific chemical blocker of mitochondrial respiratory complex I
(rotenone) to determine whether phosphorylation of AKT
depended on mitochondrial ROS. As shown in Figure 3I,
mitochondrial complex I inhibitor rotenone showed a significant
inhibition of E2-induced AKT phosphorylation. The known
chemical inhibitor of PI3K, which regulates AKT activation,
LY294002, was used as a positive control and confirmed that E2
increased the level of p-AKT in MCF-7 cells (Figure 3I). These data
support that E2-induced ROS signalling occurs upstream of AKT
and E2-induced ROS inactivation of PTEN may allow the
increased phosphorylation of the known downstream kinase
AKT. Taken together, these findings suggest that ERK or AKT
individually or in concert are susceptible to E2-induced ROS-
mediated phosphorylation.
Endogenous ROS regulated AKT-mediated phosphorylation of
NRF-1. To further investigate the mechanism by which the redox
regulation of AKT by E2-induced ROS controls growth of MCF-7
cells, we examined the effects of E2 on the redox-sensitive
transcription factor NRF-1 (known to control mitochondrial
biogenesis as well as the fate of cells) in the presence or absence
of ROS or AKT modifiers. First, we evaluated whether the oxidant-
dependent phosphorylation of NRF-1 is a function of AKT-
dependent signalling by in vitro kinase assays using recombinant
human NRF-1 and active recombinant human AKT. Serine-
phosphorylated wild-type NRF-1 was detected only in the presence
of AKT (Figure 4A). Next, we used mass spectrometry to identify
the specific serine or threonine site(s) and tyrosine phosphoryla-
tion sites on NRF-1 that was phosphorylated by the kinase. The
MS/MS spectrum for the NRF-1 peptide containing phospho-
threonine at residue 109 (observed mass of peptide sequence 106–114
ATLDEYTTR is shown in Figure 4B). This site has been previously
reported to be phosphorylated by AKT in murine cells (Piantadosi
and Suliman, 2006). Our data also showed that tyrosine residues 215
(Y215) and 326 (Y326) were phosphorylated by recombinant kinase
AKT (data not shown). Two other novel serine residues at 91
(observed mass of peptide sequence 82–93 RPHVFESNPSIR) and at
127 (observed mass of peptide sequence 115–134 VGQQAIVL-
CISPSKPNPVFK), which is theoretically predicted to be a consensus
acetylating site (SPSKP), are also targeted by AKT (data not shown).
Phosphorylation on serines 39, 44, 46, and 48 targeted by CKII
(Herzig et al, 2000) and serine 51 targeted by cyclin D1 (Wang et al,
2006) was not detected by mass spectrometry.
To provide further evidence supporting the in vitro kinase assay
observation that AKT phosphorylates NRF-1, we conducted co-IP
experiments to determine whether E2 treatment increased NRF-1/
AKT protein–protein interactions. As shown in Figure 4C,
endogenous NRF-1 co-IP with AKT and this interaction was
increased by E2 exposure (367.1 pM for 30min) of MCF-7 cells.
This protein–protein interaction was determined to be specific
because the NRF-1-containing lysates were not IP with non-
immune rabbit serum (data not shown). To confirm that AKT
controls NRF-1 phosphorylation, we examined the effect of
shRNA-mediated AKT1 knockdown on NRF-1 phosphorylation.
As shown in Figure 4D–F, cells transfected with AKT1 shRNA had a
lower level of AKT1 in MCF-7 cells. We observed that phosphoryla-
tion of NRF-1 was markedly lower upon E2 treatment in AKT1
shRNA cells compared with cells transfected with non-targeting
control scrambled shRNA cells, while NRF-1 protein levels were not
affected by AKT1 silencing in MCF-7 cells. (Figure 4D–F). Taken
together, these data implicate that NRF-1 is a physiological substrate
of AKT1. Using AKT1 shRNA, we also confirmed whether silencing
the suspected upstream kinase responsible for phosphorylation of
NRF-1 in E2-treated MCF-7 cells would have an inhibitory effect on
colony formation. As expected, cells that were transfected with AKT1
shRNA showed a much lower frequency of colonies after E2
treatment compared with the cells transfected with non-targeting
control shRNA (Figure 4G).
Based on our previous findings that show that NRF-1 is a
substrate of the kinase AKT, we determined whether NRF-1
phosphorylation was increased in MCF-7 cells. As shown in
Figure 4H, we observed more than a two-fold increase in phospho-
NRF-1 in E2-treated (367.1 pM for 30min) MCF-7 cells. To
confirm our results from western blots, we used immunofluores-
cence microscopy to evaluate NRF-1 phosphorylation. As shown in
Figure 4I, colocalisation of two antibodies (anti-phosphoserine and
anti-NRF-1) was used to measure the level of phospho-NRF-1.
Phosphorylated serine was captured as blue, and NRF-1 was
captured as red. Colocalisation of phosphorylated serine and NRF-
1 yielded pink staining, which served as an indicator of phospho-
NRF-1. Phospho-NRF-1 colocalised mainly in the nuclei after E2
treatment (Figure 4I). As shown in Figure 4H and J, phosphoryla-
tion of NRF-1 was inhibited by cotreatment with either biological
(CAT or MnSOD) or chemical (20 mM ebselen) ROS modifiers.
These results suggest that E2-induced phosphorylation of NRF-1 is
influenced by ROS signalling messengers.
Silencing of NRF-1 and AKT inhibited E2-induced MCF-7 colony
formation. Next, we evaluated whether NRF-1 or AKT expres-
sion was required for E2-induced stimulation of anchorage-
independent growth. We altered the levels of these proteins by
their respective shRNA targeting their mRNAs in MCF-7 cells
and examined whether silencing of NRF-1 or AKT1 was able to
inhibit E2-induced colony formation. As shown in Figure 4K,
shRNA targeting NRF-1 inhibited the expression of both NRF-1
and phospho-NRF-1 proteins in MCF-7 cells. As expected, the
shRNA silencing of NRF-1 led to the downregulation of TFAM,
an NRF-1 target gene (Figure 4K). In addition, knockdown of
NRF-1 resulted in the inhibition of anchorage-independent
growth of MCF-7 cells in both vehicle control- and E2-treated
cells (Figure 4L). Furthermore, we determined whether the
observed reduction in colonies was due to cell death from NRF-1
knockdown. The percent of viable cells in NRF-1 knockdown
were very similar to control cells (Figure 2H). Furthermore,
knockdown of NRF-1 resulted in the inhibition of E2-induced
ROS, which was to be expected as we have already shown that
mitochondria are the major source of ROS in MCF-7-exposed
cells. We also observed an inhibition of DNA synthesis in
E2-exposed MCF-7 cells by the RNA interference (RNAi)
silencing of NRF-1.Taken together, these findings support the
idea that NRF-1 may have an important role in E2-induced
growth of MCF-7 cells.
Endogenous ROS production regulated E2-induced NRF-1-
dependent transcriptional activation of cell cycle genes. Based
on our data that showed inhibited E2-induced DNA synthesis by
silencing NRF-1 mRNA expression in MCF-7 cells, we postulated
that E2-induced ROS signalling is involved in the modulation of
NRF-1-dependent cell cycle genes. Our next investigations used a
ChIP promoter assay to determine whether ROS modifiers altered
NRF-1 binding to the promoters of cell cycle genes that are known
to be regulated by this transcription factor. As shown in Figure 5A
and B, we observed NRF-1 bound to the promoters of CDC2,
PRC1, PCNA, cyclin B1, and CDC25C and confirmed that these
promoters contain NRF-1 elements. We also found that E2-treated
MCF-7 cells showed increased NRF-1 binding to the promoters of
these genes. NRF-1 binding induced by E2 treatment was inhibited
by the overexpression of CAT and MnSOD. Next, we determined
whether an increase in cell cycle gene expression occurred as a
result of ROS-dependent NRF-1 binding to the respective
promoters of these genes. We observed a significant increase in
the mRNA expression of CDC2, PRC1, PCNA, cyclin B1, and
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CDC25C (Figure 5C). Overexpression of MnSOD or CAT
inhibited E2-induced expression of CDC2, PRC1, PCNA, cyclin
B1 and CDC25C when compared with E2 treatment alone. These
results suggest that E2-generated ROS signal NRF-1 binding to the
promoter of cell cycle genes and thus control the expression of
these cell cycle genes.
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representative of three independent experiments±s.d. (G). Comparison of the effect of AKT shRNA treatment on E2-induced MCF-7 colonies
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(L) Comparison of the effect of NRF-1 shRNA treatment on E2-induced MCF-7 colony formation after 21 days. Upper panel graph indicates CTRL
wild-type, E2 wild-type, and CTRL shRNA. Middle panel graph indicates CTRL shRNA + E2, NRF-1 shRNA, and NRF-1 shRNA + E2. Lower panel
graph indicates significant reduction in the number of E2-induced colonies by inhibition of NRF-1 expression. Values for the number of colonies
shown as fold change compared with control. Values represent mean±s.d. Data shown in each panel of this figure are representative of three
independent experiments, unless otherwise indicated. *Po0.05, significant difference from control. **Po0.05, significant difference from E2.
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Endogenous ROS regulated antioestrogen signalling. Although
the primary mechanism of the E2 antagonist TAM is considered to
work through its inhibition of ER activation, research over the
years has indicated that additional non-ER-mediated mechanisms
exist. The prevention of breast cancer cell growth by blocking ER
signalling with chemicals such as TAM does not necessarily mean
that this compound inhibits cancer only through the competitive
binding of the receptor. As TAM can block the metabolism/redox
cycling of E2 as well as act like free radical scavengers (Arteaga
et al, 2003), it is possible that the therapeutic effect of this chemical
in part occurs through the inhibition of endogenous ROS signals
to nuclear regulatory proteins. Therefore, we also investigated
the ability of MCF-7 cells to produce ROS in response to exposure
with TAM at a pharmacological concentration of 1 mM. Using
immunofluorescence microscopy, we observed an increase of
intracellular DCFH intensity in MCF-7 cells exposed for 30min to
TAM (shown in green in Figure 6A). Cell mitochondria were also
labelled by MitoTracker Red and the merged yellow colour
represents ROS formation specific to mitochondria compared with
the vehicle control cells. Our results that show TAM indeed
increased the intracellular level of ROS is corroborated by another
study of TAM-induced ROS in MCF-7 cells (Kallio et al, 2005).
The ability of TAM to produce ROS was inhibited by treatment
with PEG-CAT (500 mgml 1) and ebselen (20 mM) (Figure 6B).
We also measured the effect of TAM treatment on the oxidation of
PTEN. We found that TAM treatment increased PTEN oxidation
(Figure 3B) and the oxidation of PTEN by these treatments was
suppressed by cotreatment with the ROS scavenger ebselen. These
results suggest that TAM-induced ROS oxidised PTEN, which is
capable of catalytic inactivation of PTEN and may result in the
increased phosphorylation of the known downstream kinase AKT.
AKT has been shown to phosphorylate ERa (Marino et al,
2003). As ROS is known to activate AKT, we investigated the
contribution of ROS to the phosphorylation of ER in E2-treated
MCF-7 cells. 17b-Oestradiol-induced phosphorylation of ERa in
the presence or absence of ROS modifiers was investigated by is
dependent on intracellular ROS production. Comparison of the
effect of ebselen on the phosphorylation of ERa was determined by
immunofluorescent microscopy. The intensity of phosphorylated
ERa at serine was remarkably high in the E2 treatment group
(367 pM for 30min) compared with the vehicle control (Figure 6C
and D). Cotreatment of E2 with the ebselen (20 mM), a potent
scavenger of H2O2, hydroperoxides, and peroxynitrite, decreased
E2-induced phosphorylation of ERa in MCF-7 cells (Figure 6C and
D). Our data are in agreement with a previous study that showed
the ROS scavenger NAC inhibited the phosphorylation of ERa
(Papa and Germain, 2011). As ERa at serine 167 is reported to be
phosphorylated by AKT (Papa and Germain, 2011), the implica-
tions of these findings suggest that E2-induced phosphorylation of
ERa may be regulated by ROS via AKT.
Next, we analysed the effect of the antioestrogen TAM on cell
cycle gene CDC25C that we previously showed was a target of
NRF-1 in E2-treated MCF-7 cells. MCF-7 cells treated with TAM
showed an increase in the mRNA levels of CDC25C compared
with vehicle control cells (Figure 6E). Our findings were consistent
with a previous report that showed, at the molecular level, TAM
recapitulates the E2-induced cell cycle gene expression in MCF-7
cells (Hodges et al, 2003). The rise in CDC25C mRNA levels in
both E2- and TAM-treated cells seems to be related to the ROS
generation because cotreatment with the ROS scavenger ebselen
inhibited their effect on CDC25C expression (Figure 6E). We also
observed a decrease in E2-induced CDC25C mRNA levels by
cotreatment with TAM, and this inhibitory effect of TAM was
partially reversed with the ebselen cotreatment. Tamoxifen alone in
the absence of E2 functions largely as an oestrogen agonist on
oestrogen target genes in MCF-7 cells and this may explain its
actions, similar to E2, in producing ROS, oxidation of PTEN, and
induction of CDC25C mRNA levels (Hodges et al, 2003; Shou et al,
2004; Penny and Roy, 2013). These findings together suggest that
ROS may also have an important role in antioestrogen-mediated
growth inhibition of breast cancer cells exposed to TAM.
ROS-dependent localisation of nuclear p27 regulates E2-induced
growth of MCF-7 cells. Recently, it has been reported that the
cyclin-dependent kinase inhibitor 1B (p27Kip1), a key protein in the
decision between proliferation and cell cycle exit, is regulated by
ROS-mediated redox signalling (Iban˜ez et al, 2012). Phosphorylation
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Figure 5. Endogenous ROS regulate NRF-1-dependent transcription
of cell cycle genes in E2-treated MCF-7 cells. Chromatin
immunoprecipitation quantitative PCR (qPCR) analysis was used to
determine NRF-1 binding to the promoters of cell cycle genes when
MCF-7 cells were treated with E2 (367nM) for 16 h. (A) Analysis of E2-
induced NRF-1 binding to promoters of PRC1 and CDC2. Graph
indicates significant reduction in bound NRF-1 to target gene
promoters when cells overexpressed ROS-scavenging enzymes
manganese superoxide dismutase (MnSOD) and catalase (CAT). (B)
Analysis of E2-induced NRF-1 binding to promoters of cyclin B1, PCNA,
and CDC25C. Graph indicates significant reduction in bound NRF-1 to
target gene promoters when cells overexpressed MnSOD and CAT.
Each ChIP value that measures bound NRF-1 to target promoter is
represented as a percentage of the respective input DNA (NRF-1
bound/input (%)). All ChIP data represent the mean±s.d. from three
independent experiments. *A statistically significant difference from
control (CTRL); **a statistically significant difference from E2 treatment.
(C) Analysis of E2-induced mRNA expression of previously described
cell cycle genes. Graph indicates significant reduction in E2-induced
gene expression when cells overexpressed enzymes CAT and MnSOD.
The relative mRNA levels measured for each gene were normalised to
18S RNA. The expression in the CTRL was set as 100%. Values are
mean±s.d. of three independent experiments. *Po0.05, significantly
different from CTRL. **Po0.05, significantly different from E2.
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and subcellular localisation of this nuclear regulatory protein are
regulated by ROS-mediated AKT signalling. The nuclear localisation
signal of p27 contains an AKT consensus site at threonine 157, and
phosphorylation of this threonine residue on p27 by AKT inhibits
p27’s import to the nucleus. This, in turn, prohibits p27 from
inhibiting cell proliferation. When p27 is in the cytoplasm, it aids in
the assembly of cyclin D1/cdk4, which furthers cell proliferation.
When the PI3K pathway has been activated, as it is in human
cancers, it has been found that p27 concentrations decrease in the
nucleus. This effect is reversed by PTEN. Overexpression of PTEN
increases p27 levels, inhibits the phosphorylation of AKT, and
through these mechanisms inhibits cell growth in MCF-7 cells
(reviewed in Penny and Roy, 2013). Based on these studies, p27 may
also be affected by ROS-mediated inactivation of PTEN in
E2-exposed MCF-7 cells. We used immunofluorescent confocal
microscopy to determine the effect that E2-induced ROS had on the
phosphorylation of T157 in p27 and subcellular localisation of p27.
In serum-starved MCF-7 cells, both the phosphorylated p27 at T157
and p27 were primarily detected within the nucleus; however, both
p27 and phospho-p27 at T157 were predominantly detected in the
cytoplasm in E2-treated MCF-7 cells (Figure 7A). The intensity of
phosphorylated p27 at T157 was remarkably high in the E2
treatment group compared with the vehicle-treated control and was
reduced by cotreatment with ebselen (Figure 7B). In MCF-7 cells
treated with only ebselen, we observed a similar distribution of both
phosphorylated p27 at T157 and p27 as observed in the control
(Figure 7A). Treatment of MCF-7 cells with erucin, which increases
TrxR2 levels and lowers oxidation of Trx, also produced a reduction
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in phosphorylation of p27 at T157 in E2-exposed cells (Figure 7C).
These findings combined with our previous data on PTEN and Trx
suggests a link between the inactivation of PTEN through its
oxidation by ROS that results in enhanced AKT phosphorylation.
The phosphorylation of T157 on p27 by an activated AKT may in
turn prevent p27 import to the nucleus and results in E2-induced
growth of MCF-7 cells via redox signalling. Another mechanism that
may contribute to the control of p27 nuclear import that is separate
from AKT phosphorylation is via a protein called Jab1. Jab1 protein
is known to shuttle p27 from the nucleus to the cytosol as a result of
a shift in Trx oxidation during the process of cell proliferation
(reviewed in Penny and Roy, 2013). As a result of E2-induced Trx
oxidation, more free Jab1 protein should be available to export p27
from the nucleus to cytosol. Thus, we extended our previous studies
on p27 to include its regulation by Jab1. We determined whether
treatment with Jab1 shRNA could suppress the growth of E2-treated
MCF-7 cells. Our results showed that shRNA-mediated Jab1
knockdown significantly inhibited E2-induced MCF-7 colony
formation (Figure 7D and E). The growth-suppressive effects of
the Jab1-shRNA support a role of Jab1–p27 interactions in the
regulation of E2-induced growth of MCF-7 cells.
DISCUSSION
The role of ROS signalling in E2-induced pathogenesis of breast
tumor has garnered much attention (Okoh et al, 2011; Penny and
Roy, 2013). Although ER signalling of cell cycle genes support the
growth of breast cancer cells, recent evidence suggests that E2-
induced ROS may also contribute in regulating survival, prolifera-
tion, and growth of breast cancer cells (Felty et al, 2005a, b). In this
study, we have demonstrated that E2-induced ROS production
may be a necessary step for the signalling cascade that supports E2-
induced growth of MCF-7 cells. This process involves oxidative
inactivation of PTPs, PTEN, and CDC25A by E2-generated ROS,
and a subsequent activation of AKT and ERK pathways that signal
downstream nuclear regulatory proteins such as NRF-1 involved in
the regulation of cell cycle genes needed for growth of breast cancer
cells (see Figure 8). Our study also showed that E2-induced ROS
influenced other nuclear proteins such as ERa, p27, and Jab1,
which contributed to the growth of MCF-7 cells. The activation of
NRF-1, ERa phosphorylation, and the impairment of p27 activity
appear to be downstream of E2-induced ROS signalling and the
AKT pathway (see Figure 8). These molecules were shown to
influence E2-induced anchorage-independent growth of MCF-7
cells. Collectively, these observations indicate a new molecular
paradigm by which ROS-inducible signal-transduction pathway(s)
may contribute to the E2-mediated growth of breast cancer.
Reactive oxygen species can instigate apoptosis, survival, and
proliferation of breast cancer cells, but these individual responses
depend on the dose (Okoh et al, 2011; Penny and Roy, 2013). The
underlying mechanism by which ROS contribute to E2-induced
growth of MCF-7 cells remains to be elucidated. Although several
nuclear regulatory proteins may be targeted by E2-generated ROS
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in MCF-7 cells, our efforts have focused on the redox-sensitive
NRF-1/a-palindrome-binding protein. Motifs bound by ELK1,
E2F, NRF-1, and NFY positively correlate with malignant
progression of breast cancer (Niida et al, 2008). Similarly, our
previous study showed that NRF-1 gene expression significantly
increases with the progression of breast tumor grades (Kunkle et al,
2009). Some of the same mitogenic pathways that are sensitive to
ROS levels and E2 are also directly regulated by NRF-1 (Okoh et al,
2011). NRF-1 is known to mediate the cellular response to
oxidative stress by regulating the expression of genes involved in
the cell cycle, DNA repair, cell apoptosis, and mitochondrial
biogenesis. However, how ROS through the redox signalling
pathway regulate NRF-1 activity in breast cancer cells remains to
be elucidated. In this study, we investigated redox signalling
pathways that not only activated NRF-1 but were also responsive to
exposures to both E2 and ROS. The activation of NRF-1 was
studied in the context of the upregulation of cell cycle genes
involved in the growth of E2-dependent breast cancer cells.
Hydrogen peroxide has been shown to oxidise and thereby
inactivate PTEN (Lee et al, 2002), which would suggest that
increased H2O2 formation upon E2 treatment may also affect
PTEN activity in MCF-7 cells. Our data showed a dose-dependent
increase in the levels of oxidised PTEN after H2O2 treatment. In
the MCF-7 cells, E2 had similar effects on PTEN oxidation and a
cotreatment with ROS scavenger ebselen inhibited this effect,
which indicates a contribution from the ROS generated from E2
treatment. Furthermore, lowering intracellular H2O2 levels by the
overexpression of CAT and by treatment with ROS scavengers
inhibited E2-induced phosphorylation of AKT, a downstream
target of PTEN/PI3K pathway. The ability of E2 and ROS to induce
phosphorylation of AKT may be attributed to the oxidation of
PTEN, which is a PI3K inhibitor. The reversible inactivation of
PTEN by E2-induced ROS may be a key component of AKT
activation. We further tested our concept using another PTP,
CDC25A. Our results showed that H2O2 or E2 treatment of MCF-7
cells produced oxidised and inactivated CDC25A. This inactivation
was prevented by a cotreatment with ROS scavenger NAC. As
CDC25A is a PTP known to interact with ERK (Wang et al, 2005),
E2-induced ROS-mediated inactivation of CDC25A could lead to a
higher level of phosphorylated ERK. Thus, it is biologically
plausible that the inactivation of CDC25A by E2-induced ROS is
responsible for ERK phosphorylation in MCF-7 cells. This
observation is consistent with our finding of PTEN oxidation,
and with earlier reports suggesting that ROS could reversibly
modify the redox state of specific cysteine residues in PTPs and
make them inactive. These findings have important implications
for understanding the molecular mechanisms by which the redox-
sensitive molecules AKT or ERK may participate in E2-mediated
signalling to NRF-1. NRF-1 was reported to be a substrate of AKT
and activation of AKT controls translocation of NRF-1 to the
nucleus. This observation is based on a study in which the
translocation of NRF-1 to the nucleus occurred in PTEN-deficient
cells and was abrogated when the PI3K pathway was blocked,
inactivating AKT (Piantadosi and Suliman, 2006). Our study
confirmed that NRF-1 is a direct substrate of AKT in the MCF-7
cells. Serine residues 97, 108, and 116 are the major sites in NRF-1
that are phosphorylated by AKT. Exposure of MCF-7 cells to E2
not only upregulated NRF-1 expression but it also induced
phosphorylation of NRF-1 by AKT kinase in a redox-dependent
manner. Treatment of cells with ROS modulators or RNAi of NRF-
1 prevented E2-induced NRF-1 expression and phosphorylation.
These findings show that AKT catalyses NRF-1 phosphorylation in
E2-treated MCF-7 cells through an ROS-mediated signalling
pathway. Our current study also showed that silencing of NRF-1
or AKT expression reduced MCF-7 colony formation. To examine
the effect of ROS production in the transcriptional activation of
NRF-1 target genes, we evaluated the effects of ROS scavengers on
NRF-1 binding to the promoters of the cell cycle genes: PRC1,
PCNA, cyclin B1, CDC2, and CDC25C. Exposure of MCF-7 cells to
E2 increased the binding of NRF-1 to promoters of these cell cycle
genes, and this E2 effect was inhibited by the overexpression of
H2O2 scavenger CAT. To further analyse the mechanism of ROS in
regulating cell cycle genes, we studied the effect of ROS scavengers
on mRNA expression of NRF-1-regulated cell cycle genes and
found that E2-induced expression of these cell cycle genes was also
inhibited by the overexpression of H2O2 scavenger CAT. These
data suggest that ROS regulate E2-induced transcriptional activa-
tion of cell cycle genes through NRF-1 modulation. Taken
together, these observations strongly support our concept that
ROS-inducible PI3K-AKT signalling pathway acts as one of the
main signal-transduction pathways triggering NRF-1 activation
and subsequent NRF-1-mediated transcription of cell cycle genes
in response to E2 exposure (Figure 8). Our findings suggest that
ROS modulators may be useful agents to inhibit the E2-induced
tumor phenotype and have the potential for further therapeutic
development.
In addition to NRF-1 signalling, ROS may also influence other
E2-regulated nuclear proteins such as ERa and p27. AKT
phosphorylates both ERa and p27. Our findings revealed that
E2-induced phosphorylation of ERa may be dependent on ROS
signalling because the ROS scavenger ebselen inhibited E2-induced
ERa phosphorylation. Although ERa is believed to regulate E2-
induced NRF-1 expression in MCF-7 cell line (Ivanova et al, 2011),
our data indicate that E2-induced ROS are also essential for
phosphorylation of both ERa and NRF-1. Furthermore, our study
revealed that AKT-mediated phosphorylation of p27 inhibited p27
import to the nucleus. The significance of this finding is that E2-
induced ROS signalling may allow for the growth of MCF-7 cells
TFAM TrxR
ROS
Trxox Jab1
CDC25Aox/p-ERK
PTENox/p-AKT
Antioxidants
Jab1-p27
p-p27(T157)
p-NRF-1
Cell cycle genes Growth of tumorsE2
Figure 8. A hypothetical scheme illustrating the role of ROS-induced signalling pathways contributing to E2-induced growth of breast cancer
through influencing nuclear regulatory proteins such as NRF-1 and p27. ROS-mediated inactivation of PTPs, CDC25A, and PTEN, presumably
leading to the activation of downstream kinases extracellular signal-regulated protein kinases 1 and 2 (ERK1/2), mitogen-activated protein kinase
(MAPK), and AKT may regulate E2-induced phosphorylation of nuclear regulatory proteins such as ERa, NRF-1, and p27. This may result in the E2-
induced activation of the proliferative stimulation leading to the colony formation. The net effect is E2-induced growth of breast cancer cells. This
hypothetical model has support from our data showing E2-induced growth of breast cancer cells can be blocked with the overexpression of ROS-
scavenging enzymes catalase or MnSOD, and by suppression of AKT and NRF-1 expression.
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by an additional mechanism such as redox-mediated sequestering
of p27 away from the nucleus, which in turn allows the cell cycle to
progress without interference by the cell cycle inhibitory protein
p27. In this study, we found that reducing the level of oxidised Trx
by overexpression of its reductase TrxR2 blocked phosphorylation
of T157 in p27 and prevented the cytosolic accumulation of
p-p27(T157) in E2-treated MCF-7 cells. Furthermore, we showed
that shifting the redox state of Trx to a more reduced state resulted
in decreased MCF-7 colony formation in E2-exposed cells as well
as decreased phosphorylation of p27 at T157, which helped to
retain the inhibitory p27 protein in the nucleus. Trx has been
shown to compete with p27 for binding with Jab1 (Pan et al, 2012;
Penny and Roy, 2013), and this negatively regulates p27
degradation. We observed that altering the redox state of cells by
overexpression of Trx reductase inhibits E2-induced colony
formation of MCF-7 cells. Decreasing Jab1 expression also led to
a decrease in E2-induced colony formation. Taken together, our
findings suggest that E2-induced growth of MCF-7 cells may not
only be regulated via NRF-1. Instead, other nuclear regulatory
proteins such as ERa may also be activated in a similar manner by
redox-sensitive kinases downstream of PTPs such as AKT. Besides
transcription factors, cell cycle inhibitory proteins such as p27 may
also be regulated by redox signalling via sequestering p27 away
from the nucleus that allows for E2-induced cell growth.
In summary, the major novel findings of this study illustrate
that the activation of NRF-1 and impairment of p27 by E2 are
dependent on ROS formation. 17b-Oestradiol generated ROS-
inactivate PTEN and CDC25A, which may activate AKT and
ERK1/2, respectively. Activated AKT and ERK1/2 phosphorylate
NRF-1 leading to the translocation of NRF-1 to the nucleus, where
it activates the transcription of cell cycle genes that control E2-
mediated anchorage-independent growth of MCF-7 cancer cells.
Findings of this study not only provide a new paradigm in
understanding the mechanism of E2-dependent growth of
malignant breast cancer cells but it also provides important
information for the design of new antioxidant-based drugs for the
prevention and treatment of oestrogen-dependent breast cancer.
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